Laboratorios Farmaceuticos Rovi, S.A. (BIT:1ROVI)

Market Cap	3.85B +14.7%
Revenue (ttm)	724.20M -9.4%
Net Income	121.15M -26.6%
EPS	2.37
Shares Out	n/a
PE Ratio	31.75
Forward PE	25.92
Dividend	0.76 (0.93%)
Ex-Dividend Date	Jul 14, 2025

Volume	n/a
Average Volume	1
Open	n/a
Previous Close	78.35
Day's Range	n/a
52-Week Range	45.95 - 81.20
Beta	n/a
RSI	59.14
Earnings Date	Feb 25, 2026

About BIT:1ROVI

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+,...

• Industry: Pharmaceutical Preparations
• Founded: 1946
• Employees: 2,188
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1ROVI

Financial Performance

In 2024, BIT:1ROVI's revenue was 763.75 million, a decrease of -7.93% compared to the previous year's 829.51 million. Earnings were 136.88 million, a decrease of -19.64%.